Journal
CNS DRUGS
Volume 25, Issue 1, Pages 17-36Publisher
ADIS INT LTD
DOI: 10.2165/11538450-000000000-00000
Keywords
-
Categories
Funding
- Janssen-Cilag
- Department of Health of the Government of Catalonia (Generalitat de Catalonia, Spain)
- Fundacion Alicia Koplowitz
- Laboratorios Rubio
- Shire
- Eli Lilly
Ask authors/readers for more resources
Remission should be the goal of attention-deficit hyperactivity disorder (ADHD) treatment. However, there is no universally accepted definition of remission in ADHD, although clinical studies use a number of criteria. This article examines current research into the concept of remission in ADHD by reviewing the literature for definition and achievement of remission in children and adults with ADHD. Results demonstrate that the concept of remission in ADHD has been proposed by several study groups, using thresholds of validated rating scales to indicate syndromic, symptomatic and functional remission. Several studies have demonstrated the achievement of remission in ADHD children utilizing methylphenidate delivered by an osmotic, controlled-release formulation (OROS (R)) and atomoxetine. However, none has defined a time period over which these criteria must be met for an individual with ADHD to be considered 'in remission'. Standardized remission criteria in ADHD will provide a tool for assessing the effectiveness of treatments for ADHD, and raise treatment standards.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available